ASSESSMENT OF INFLAMMATORY STATUS IN TYPE 2 DIABETES MELLITUS PATIENTS
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i9.26733Keywords:
C-reactive protein, Type 2 diabetes mellitus, Inflammation, Fasting blood glucose, Glycated hemoglobinAbstract
Objective: The metabolic disorder, Type 2 diabetes mellitus (T2DM), is a major health problem which is the risk factor for the development of cardiovascular disease, cerebrovascular accident, renal failure, and other macrovascular diseases. Inflammation is the major pathogenesis of all the above conditions. Therefore, there is a need to assess the inflammatory status using simple and reliable marker which would help to diagnose the disease and assess the prognosis of the disease. Hence, the aim of the current study is to estimate the level of simple inflammatory marker, C-reactive protein (CRP) in Type 2 diabetes individual.
Materials and Method: Fifty patients, reporting to Saveetha Dental College and Hospitals, were enrolled in the study which includes 25 patients with T2DM and 25 healthy individuals. 5 ml of venous blood was collected and centrifuged. Then, it is analyzed for fasting blood sugar (FBS), glycated hemoglobin (HbA1c), and CRP using the standard kit method. The data obtained were subjected to statistical analysis using the SPSS software.
Results: The mean FBS, HbA1c, and CRP levels were higher in T2DM patients in comparison to healthy individuals. The serum FBS, HbA1c, and CRP levels in the control group and T2DM group were 85.08±8.47, 4.27±0.63, and 6.51±0.83 and 168, 7.38±0.9, and 27.23±19.06, respectively. There was a significant (p=0.000) difference in the mean CRP levels of the above groups.
Conclusion: CRP level were consistently higher in T2DM individuals; hence, it could be a simple and reliable marker to assess the inflammatory status of the diabetic individuals.
Downloads
References
Mahajan A, Tabassum R, Chavali S, Dwivedi OP, Bharadwaj M, Tandon N, et al. High-sensitivity C-reactive protein levels and Type 2 diabetes in urban north Indians. J Clin Endocrinol Metab 2009;94:2123 7.
Chowdhury TA, Hitman GA. Type 2 diabetes in people of South Asian origin. Br J Diab Vasc Dis 2007;7 Suppl 6:279-82.
Ramachandran A, Mary S, Yamuna A, Murugesan N, Snehalatha C. High prevalence of diabetes and cardiovascular risk factors associated with urbanization in India. Diabetes Care 2008;31:893-8.
Mohan V, Deepa M, Deepa R, Shanthirani CS, Farooq S, Ganesan A, et al. Secular trends in the prevalence of diabetes and impaired glucose tolerance in urban south India--the Chennai urban rural epidemiology study (CURES-17). Diabetologia 2006;49:1175-8.
Anjana RM, Pradeepa R, Deepa M, Datta M, Sudha V, Unnikrishnan R, et al. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: Phase I results of the Indian council of medical research-INdia DIABetes (ICMR-INDIAB) study. Diabetologia 2011;54:3022-7.
Singh PS, Sharma H, Zafer KS, Singh PK, Yadav SK, Gautam RK, et al. Prevalence of Type 2 diabetes mellitus in rural population of India-a study from the western Utter Pradesh. Int J Res Med Sci 2017;5 Suppl 4:1363-7.
Andayani TM, Ibrahim MI, Asdie AH. The association of diabetes– related factor and quality of life in Type 2 diabetes mellitus. Int J Pharm Pharm Sci 2010;2 Suppl 1:139-45.
Beh T, Goel H, Kaur I, Sudan P, Sharma M, Misri RW, et al. Role of C reactive protein in diabetes mellitus and its associated complications. Indo Am J Pharm Res 2014;4 Suppl 11:5315-20.
Chase HP, Cooper S, Osberg I, Stene LC, Barriga K, Norris J, et al. Elevated C-reactive protein levels in the development of Type 1 diabetes. Diabetes 2004;53:2569-73.
Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem 2004;279:48487-90.
Aguiar FJ, Ferreira-Júnior M, Sales MM, Cruz-Neto LM, Fonseca LA, Sumita NM, et al. C-reactive protein: Clinical applications and proposals for a rational use. Rev Assoc Med Bras (1992) 2013;59:85 92.
Salazar J, Martinez MS, Chavez M, Toledo A, Anez R, Torres Y, et al. C-Reactive protein: Clinical and epidemiological perspectives. Cardiol Res Pract 2014. Article ID: 605810: 10 Pages.
Ingle PV, Patel DM. C-reactive protein in various disease condition–an overview. Asian J Pharm Clin Res 2011;4 Suppl 1:9-13.
Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998;97:596.
Robertson RP, Antagonist: Diabetes and insulin resistance-philosophy, science, and the multiplier hypothesis. J Lab Clin Med 1995;125 Suppl 5:560-4.
Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: A review of current trends. Oman Med J 2012;27 Suppl 4:269-73.
Shari SB, Nadar R, Paul MR. High sensitive C-reactive protein: Clinical importance. Curr Probl Cardio 2004;12:1-12.
Bhaktha G, Shantaram M, Nayak S, Nagendra S. Relationship of HS-CRP level in the diabetic persons free from micro and macrovascular disease. Int J Res Dev Pharm L Sci 2014;3 Suppl 4:1070-3.
Steinberg D. Antioxidants and atherosclerosis. A current assessment. Circulation 1991;84:1420-5.
Chiu JJ, Wung BS, Shyy JY, Hsieh HJ, Wang DL. Reactive oxygen species are involved in shear-stress induced intracellular adhesion molecule-1. Expression in endothelial cells. Arterioscler Thromb Vasc Biol 1997;17:3570-7.
Jialal I, Devaraj S, Venugopal SK. C-reactive protein: Risk marker or mediator in atherothrombosis? Hypertension 2004;44:6-11.
Sarinnapakorn V, wanicagool W. Assocition between hs-CRP and HbA1c in over weight Type 2 diabetic female patients. J Med Assoc Thai 2013;96 Suppl 3:54-8.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
